Sélectionner une page

A day in the life of InnoSer Organ-on-Chip product manager Alex Bastiaens.

organ-on-chip product manager
November 24, 2020
Alex Bastiaens InnoSer Interview

Afin de proposer une gamme d’outils innovants destinés à accélérer le développement de médicaments, InnoSer rassemble des professionnels issus aussi bien du monde scientifique que du monde des affaires. Grâce à notre série d’entretiens« Une journée dans la vie de… », découvrons ensemble ce que signifie faire partie de cette petite équipe polyvalente et dynamique !

Éducation

PhD biomedical engineering

Basée à

 Leiden &
Eindhoven

Boîte à outils

Neuronal cells, micro-/nano-fluidics, MATLAB

}

Chez InnoSer depuis

October
2019

Alex wears two hats: One as a postdoctoral researcher in the Neuro-Nanoscale Engineering group of dr. Regina Luttge at the Eindhoven University of Technology (TU/e), and another as the Organ-on-Chip (OoC) product manager at InnoSer. While he cooks the microfluidics technologies at the Luttge kitchen, his work at InnoSer mainly entails the coordination of collaborative projects on OoC models for neurodegenerative diseases, with tasks including project management meetings, project planning, and financial reporting. He works closely with biomedical engineer Teun van Nunen, who is responsible for preparing cell cultures, and Marcel ter Veld, director of operations and services, for monitoring the project timeline, milestones and the progress on work packages.

The team is currently developing Brain-on-Chip (BoC) platform as part of MINDMAP, a Eurostars funded project (E!113501) within a multidisciplinary consortium that aims to provide a powerful in vitro tool for screening drugs against Alzheimer’s disease. BoC is a micro-scale model used for mimicking the 3D structural and functional environment of the human brain. Alex says, “BoC allows us to use healthy or patient human resources via induced pluripotent stem cell (iPSC) technology in a microenvironment with well defined analytical components, and in comparison to 2D models, it introduces more control and less heterogeneity between samples.”

Since the project began in October 2019, Alex and his colleagues built up the infrastructure to facilitate cell culture and BoC models, gathered resources from consortium partners, and they are working towards the integration of the separate components of the prototype. “Our next step will be to develop intelligent ways to get better predictors from results, such as those obtained from electrophysiological recordings and calcium imaging, and eventually, speed up drug screening processes.” The MINDMAP project will be concluded in 2022.

“We discuss the project progress with the people in the lab in biweekly meetings. Although I am based in Leiden, I also try to visit Diepenbeek, starting my day at the office as early as 7:30. So on those days, you know I’m one of the first to use the coffee machine. But I don’t mind, since this means I don’t get caught in traffic. It also allows me to leave early to spend time with my 2 kids, and have dinner together. They like helping with dinner preparations, as long as it’s not vegetables!”

Because of COVID-19 restrictions, Alex spent more time staying at home in the past months and on project coordination instead of working in the lab. “Luckily, we can focus on different stages of the project so we can minimize any delays. Though, it is of course much more motivating to be close to your colleagues. People at InnoSer have different backgrounds, and they are all passionate about their work, so our interactions can generate a lot of useful ideas.”

“Combining this team spirit with the fact that we have goals with huge impacts on patients makes my work very fulfilling on a personal level.” Alex says he is always hungry to learn more and to solve puzzles. The most challenging parts of his job are the ones he likes the most as well. “Making a fully functional product for customers by using multidisciplinary technologies is a great challenge. Together with experts in the field, we combine microfabrication, iPSC technology and AI. Understanding these components in depth and always keep improving them are great motivators.”

About Alex

Alex completed a bachelor in Biomedical Engineering and a master in Biomechanics and Tissue Engineering, both at the TU/e. He then worked on in vitro brain models using micro- and nano-engineered neuronal cell networks as part of his PhD, also at TU/e. Alex now works part-time as a postdoctoral researcher, expanding on his work in Regina Luttge’s group, and oversees relevant developments for InnoSer’s Brain-on-Chip platform as product manager. He also enjoys Arduino DIY-projects and printing 3D resin structures, which he hopes may someday benefit work in the lab at InnoSer.

Partagez cet article sur les réseaux sociaux ! [DISPLAY_ULTIMATE_SOCIAL_ICONS]

Articles récents

Le volume rénal total (TKV) : un indicateur non invasif de l'évolution de la maladie, pertinent sur le plan translationnel

Le volume rénal total (TKV) : un indicateur non invasif de l'évolution de la maladie, pertinent sur le plan translationnel

Dans la newsletter de ce mois-ci, nous vous invitons à découvrir comment l'évaluation longitudinale du volume rénal total (TKV) réalisée par InnoSer à l'aide d'une imagerie échographique non invasive sur notre modèle murin de PKD autosomique dominante fournit des données structurelles en phase avec la pratique clinique, qui facilitent directement la prise de décision dans...

En savoir plus
Panels de biomarqueurs cliniquement pertinents pour des études d'efficacité exhaustives sur des modèles murins de la maladie d'Alzheimer

Panels de biomarqueurs cliniquement pertinents pour des études d'efficacité exhaustives sur des modèles murins de la maladie d'Alzheimer

Les modèles murins validés d'InnoSer pour la maladie d'Alzheimer (MA) intègrent des panels de biomarqueurs pertinents sur le plan translationnel — couvrant les espèces de bêta-amyloïde (Aβ), les isoformes phosphorylées de la protéine Tau, ainsi que le marqueur précoce et sensible de la neurodégénérescence que constituent les neurofilaments légers...

En savoir plus

Toutes les catégories

Soyez les premiers informés : recevez ces actualités directement dans votre boîte mail

InnoSer propose toute une gamme de plateformes validées in vitro et in vivo permettant le développement efficace de nouveaux traitements. Si vous souhaitez obtenir des informations complémentaires, n'hésitez pas à nous contacter ; nous vous répondrons dans les jours qui suivent.

Nous publions chaque mois une lettre d'information de nos laboratoires InnoSer, qui présente des informations scientifiques sur nos services de recherche. Pour recevoir ces actualités directement dans votre boîte mail, inscrivez-vous ici.